Add Novavax press release about PREVENT-19 phase 3 trial

README.md

@@ -363,6 +363,7 @@ Note that the WHO will generally be unable to make statements that their more pr
 * [Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly](https://www.sanofi.com/en/media-room/press-releases/2020/2020-12-11-07-00-00) in a press release where they disclose that while the vaccine produces an immune response similar to COVID-19 patients when administered to people between 18 and 49 years, the response in older adult is insufficient
 * [Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial](https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3), as announced in a press release by the company about their NVX-CoV2373 protein-based vaccine, based on a trial that included 27% over the age of 65, and on an interim analysis after 62 cases developed, of which 56 were in the placebo group; at the same time, [Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant](https://www.medrxiv.org/content/10.1101/2021.02.25.21252477v1) in South Africa was 60% (among HIV-negative individuals), likely due to 90% prevalence of the South African escape variant, which the company says has initiated development of boosters for
 * [Novavax announcement of UK and South AfricaTrial Results](https://www.novavax.com/sites/default/files/2021-01/UK-SouthAfrica%20-Trial-Results.pdf) is fairly boasting ("breaking news", seriously?) but contains a lot of nice infographics and variant spread graphs
+* [Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial](https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-90-overall-efficacy-and) with 29,960 in the United States and Mexico, among which 63 cases of COVID were seen in the placebo group and 14 in the vaccine group, and the efficacy appears to remain high in patients with sequenced variants of concern
 * [Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial](https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial), with an overall efficacy of 66% using a single-shot scheme, although the efficacy was 72% in the US and 57% in South Africa, possibly owing to the variant there (95% of cases), and 85% effectiveness in preventing severe disease, and the vaccine was well tolerated
 * [FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine](https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine) after the document [Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19 briefing document](https://www.fda.gov/media/146217/download) was released by the FDA endorsing the Johnson&Johnson vaccine; [Derek Lowe](https://blogs.sciencemag.org/pipeline/archives/2021/02/24/the-jj-vaccine-at-the-fda) and [StatNews](https://www.statnews.com/2021/02/24/new-data-shed-light-on-efficacy-of-jjs-single-dose-vaccine-against-covid-19/) discuss the data
 * [Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext) presents the first phase 3 results for the Sputnik V vaccine, with an estimated efficacy of 91.6%, and no serious adverse effects associated with vaccination